biostudies-literatureUnknown16(4)Elnaggar MNovo Nordisk Ltd<h4>Introduction</h4>Glucagon-like peptide-1 (GLP-1) receptor agonists represent efficacious therapies for treating type 2 diabetes. Oral semaglutide is the only orally administered GLP-1 receptor agonist currently available and has been associated with reductions in glycated hemoglobin and body weight versus once-daily injectable liraglutide after 52 weeks in the PIONEER 4 clinical trial. As lower-cost liraglutide formulations have recently been developed, the present analysis evaluated the long-term cost-effectiveness of oral semaglutide 14 mg versus liraglutide 1.8 mg at lower acquisition costs in the UK.<h4>Methods</h4>The published and validated PRIME Type 2 Diabetes Model was used to project clinical and cost outcomes over patient lifetimes. Baseline cohort characteristics, as well aDiabetes therapy : research, treatment and education of diabetes and related disorders613-628https://www.ebi.ac.uk/biostudies/studies/S-EPMC11926313biostudies-literatureThe Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.PMC11926313Mansinho JNHunt BWhitaker JGlah DAli SMalkin SJPElnaggar MMacLellan MfalseThe Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.<h4>Introduction</h4>Glucagon-like peptide-1 (GLP-1) receptor agonists represent efficacious therapies for treating type 2 diabetes. Oral semaglutide is the only orally administered GLP-1 receptor agonist currently available and has been associated with reductions in glycated hemoglobin and body weight versus once-daily injectable liraglutide after 52 weeks in the PIONEER 4 clinical trial. As lower-cost liraglutide formulations have recently been developed, the present analysis evaluated the long-term cost-effectiveness of oral semaglutide 14 mg versus liraglutide 1.8 mg at lower acquisition costs in the UK.<h4>Methods</h4>The published and validated PRIME Type 2 Diabetes Model was used to project clinical and cost outcomes over patient lifetimes. Baseline cohort characteristics, as well a2025-01-01T00:00:00Z2025 Apr2025-04-26T05:50:09.901Z2025-04-06T11:38:28.87ZS-EPMC119263133996975510.1007/s13300-025-01691-1